CORRECTION: Sequenom's Q3 Revenues Drop 20 Percent as Net Loss Swells 43 Percent | GenomeWeb

This article has been corrected from an earlier version that said that Sequenom had "shelved" its SEQure Dx test following an investigation into mishandled data. The firm is continuing development of the test.

NEW YORK (GenomeWeb News) – Sequenom said after the market closed today that its third-quarter revenues dropped 20 percent while its net loss increased 43 percent.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: Neanderthal-derived DNA linked to modern ailments, and more.

Japan needs to catch up on its gene-editing research efforts, the Japan News writes.

Hundreds of people have signed an online petition calling for zero tolerance to sexual harassment in the sciences.

Jeff Huber, former Google X senior vice president, joins Grail as its CEO.

Mar
03
Sponsored by
Agilent Technologies

This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies.